Log in

ISPC iSpecimen Inc. NASDAQ · United States

iSpecimen (ISPC) news ISPC reverse split, offering and merger news

Latest iSpecimen news

  1. Listings

    iSpecimen agrees to buy Foldlab AI software assets for $4,500,000

    The deal pays $2,000,000 in cash, including milestone payments, and $2,500,000 in stock held in a five-year escrow.

  2. Company Updates

    iSpecimen signs $2,000,000 investor relations consulting agreement

    IR Agency LLC will provide news distribution for up to ten releases over a three-month term, and the fee is fully earned on receipt.

  3. Financings

    iSpecimen prices $5 million public offering at $1.30 per share

    E.F. Hutton & Co. is the exclusive placement agent, and the offering is expected to close on August 7, 2026.

  4. Debt Financing

    BioRestorative sets up $1,000,000 revolving loan from Bowery Group

    BioRestorative Therapies can borrow up to $1,000,000 from Bowery Group LLC at 12%, and the same agreement brought three director resignations and three new directors designated by the lender. Its cash use in 2025 was $10.8 million.

  5. Listings

    iSpecimen prices $2.5 million private placement at $5.12 per share

    E.F. Hutton & Co. is the exclusive placement agent, and the company expects the offering to close on or about May 11, 2026.

  6. Listings

    iSpecimen plans 1-for-40 reverse stock split effective April 27, 2026

    After the split, the company's 52,639,796 shares become 1,316,032 shares, and the stock trades split-adjusted from April 28, 2026.

iSpecimen annual financials

LineFY2025FY2024
Revenue$1.9 million$9.3 million
Research and development$1.5 million
Net income (loss)-$10.5 million-$12.5 million
Cash from operations-$4.2 million-$8.3 million
Cash and equivalents$6.9 million$1.9 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $4.4 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about iSpecimen

Did iSpecimen do a reverse stock split?

Our latest story on this, dated Apr 24, 2026: "iSpecimen plans 1-for-40 reverse stock split effective April 27, 2026". The story links the filing or release it is based on. Read the story.

Has iSpecimen raised money recently?

Our latest story on this, dated Sep 8, 2026: "iSpecimen gets until November 25, 2026 to meet Nasdaq equity rule". The story links the filing or release it is based on. Read the story.

Is iSpecimen involved in a merger or acquisition?

Our latest story on this, dated Sep 4, 2026: "iSpecimen agrees to buy Foldlab AI software assets for $4,500,000". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of iSpecimen?

iSpecimen Inc. trades under the ticker ISPC on NASDAQ.

Where is iSpecimen listed?

iSpecimen Inc. is listed on NASDAQ.

Which country or territory is iSpecimen listed under?

Our directory records iSpecimen Inc. under United States.

Does aibio.space cover iSpecimen?

aibio.space lists iSpecimen Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

What was iSpecimen's revenue last year?

$1.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is iSpecimen profitable?

iSpecimen Inc. reported a net loss of $10.5 million for the fiscal year ended Dec 31, 2025, and used $4.2 million of cash in operations, per its annual report to the SEC.

How much cash does iSpecimen have?

$4.4 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest iSpecimen (ISPC) stock news?

Our latest story on iSpecimen, dated Sep 8, 2026: "iSpecimen gets until November 25, 2026 to meet Nasdaq equity rule". The company plans a public offering of approximately $5 million, and its projections show stockholders' equity of approximately $5.1 million through June 30, 2027. Source.

How long will iSpecimen's cash last?

From our story of May 8, 2026: The release also cites the risk that the company may not maintain compliance with the continued listing standards of The Nasdaq Capital Market, the substantial doubt about its ability to continue as a going concern, and its need for additional financing. Source.

Which other companies' news mentions iSpecimen?

iSpecimen is named in 1 of our story about other companies, most recently: "BioRestorative sets up $1,000,000 revolving loan from Bowery Group" (Jun 10, 2026). Source.

How can I follow iSpecimen (ISPC) news?

Press Follow on this page to add iSpecimen to your Following list, or subscribe to the aibio.space newsletter. We have published 7 stories naming iSpecimen so far, in Company Updates, Debt Financing, Financings, Listings.

Investor discussion: iSpecimen

Members talk about iSpecimen (ISPC). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at iSpecimen, newest first. Each line links the filing it comes from.

  1. Listings

    Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source

  2. Listings

    Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source

  3. Listings

    Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source

  4. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source

  5. Listings

    Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source

  6. Financings

    Filed a registration statement for a share offering. SEC Form S-1. Source

  7. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source

  8. Distress

    Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source

  9. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,3.01,3.02,7.01,8.01,9.01). Source

  10. Listings

    Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:ISPC on TradingView.

Listing details

iSpecimen Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ISPC, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
iSpecimen Inc.
Ticker
ISPC
Listing
NASDAQ
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.